Kawasaki Disease (KD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Kawasaki Disease (KD) Market Outlook

Thelansis’s “Kawasaki Disease (KD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Kawasaki Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Kawasaki Disease (KD) Overview

Kawasaki disease (KD), also referred to as mucocutaneous lymph node syndrome, is an acute medium vessel vasculitis characterized by a preference for the coronary arteries. It is the primary cause of acquired heart disease in developed nations and is progressively surpassing rheumatic heart disease in developing countries. The precise etiology of Kawasaki disease remains unknown, but it may be associated with an airborne or waterborne pathogen. Typically, affected children initially manifest with a high fever that exhibits a remittent pattern and lasts for approximately one to two weeks without treatment. In some instances, the fever may persist for up to three to four weeks. Additional distinctive features include bilateral conjunctivitis (inflammation of the whites of the eyes), inflammation of the mucous membranes of the mouth and throat leading to dry, red, cracked lips and a strawberry-red tongue, cervical lymphadenopathy (swelling of lymph nodes in the neck), redness and swelling of the hands and feet, and a reddish rash that typically affects the trunk and often extends to the groin area. The prognosis of Kawasaki disease depends on the severity of cardiac involvement. Furthermore, the prognosis is more favorable for children diagnosed between the ages of 6 months and 9 years compared to those younger or older, possibly due to earlier diagnosis following the presentation of classic symptoms. Recurrence is infrequent but more likely in younger children who experienced cardiac complications during the initial episode of the disease. All deaths related to Kawasaki disease are primarily attributed to cardiac complications and typically occur within 15-45 days from the onset of fever. The disease can lead to the formation of aneurysms, heart failure, myocardial infarction (MI), myocarditis, valvulitis, pericarditis with pericardial effusion, and rupture of the coronary arteries resulting in hemopericardium and sudden death. Approximately 9% of patients experience acute phase cardiac complications, while about 3% develop cardiac sequelae. Patients with Kawasaki disease frequently experience myocardial infarctions during sleep or rest, suggesting a potential etiology involving coronary vasospasm. Myocardial inflammation is observed in 50 to 70% of patients during the acute phase of the disease, raising concerns about the long-term impact of Kawasaki disease on cardiac function. Kawasaki disease is most commonly observed in children under five and can manifest at any age, including adulthood.

• In the USA, the estimated incidence of Kawasaki disease, based on hospital discharge data, is approximately 25 cases per 100,000 children under the age of five.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: